{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:35:08Z","timestamp":1763415308399,"version":"build-2065373602"},"reference-count":58,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.revmed.2013.02.031","type":"journal-article","created":{"date-parts":[[2013,6,3]],"date-time":"2013-06-03T18:16:56Z","timestamp":1370283416000},"page":"438-443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Complications de la corticoth\u00e9rapie chez les patients souffrant de maladie de Horton ou de pseudopolyarthrite rhizom\u00e9lique"],"prefix":"10.1016","volume":"34","author":[{"given":"L.","family":"Fardet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2013.02.031_bib0005","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.revmed.2011.02.022","article-title":"Description des prescriptions de corticoth\u00e9rapies orales en population g\u00e9n\u00e9rale","volume":"32","author":"Fardet","year":"2011","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2013.02.031_bib0010","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2165\/00002018-200730100-00005","article-title":"Corticosteroid-induced adverse events in adults: frequency, screening and prevention","volume":"30","author":"Fardet","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.revmed.2013.02.031_bib0015","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0248-8663(05)81208-1","article-title":"[Benefits of corticosteroids in the treatment of Horton's disease and rhizomelic pseudopolyarthritis: advantages and inconveniences. A meta-analysis]","volume":"13","author":"G\u00e9n\u00e9reau","year":"1992","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2013.02.031_bib0020","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0248-8663(01)00399-X","article-title":"[Horton's disease in elderly patients aged over 75: clinical course, complications of corticotherapy. Comparative study of 164\u00a0patients. Towards a reduced initial dose]","volume":"22","author":"Chevalet","year":"2001","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2013.02.031_bib0025","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2013.02.031_bib0030","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.revmed.2013.02.031_bib0035","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes","volume":"49","author":"Proven","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2013.02.031_bib0040","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/art.1780401022","article-title":"Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica","volume":"40","author":"Gabriel","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2013.02.031_bib0045","first-page":"1283","article-title":"Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43\u00a0patients","volume":"21","author":"Nesher","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2013.02.031_bib0050","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.revmed.2013.02.031_bib0055","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","article-title":"Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial","volume":"141","author":"Caporali","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.revmed.2013.02.031_bib0060","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/art.22163","article-title":"Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial","volume":"54","author":"Mazlumzadeh","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2013.02.031_bib0065","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.55.4.218","article-title":"Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?","volume":"55","author":"van der Veen","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2013.02.031_bib0070","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/rheumatology\/37.2.189","article-title":"An initially double-blind controlled 96\u00a0week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica","volume":"37","author":"Dasgupta","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.revmed.2013.02.031_bib0075","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1136\/ard.47.9.733","article-title":"Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11\u00a0year survey of 210\u00a0patients)","volume":"47","author":"Delecoeuillerie","year":"1988","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2013.02.031_bib0080","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3899\/jrheum.110851","article-title":"Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study","volume":"39","author":"Mazzantini","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2013.02.031_bib0085","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/acr.21569","article-title":"Incidence of infections in patients with giant cell arteritis: a cohort study","volume":"64","author":"Durand","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.revmed.2013.02.031_bib0090","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1093\/rheumatology\/keq200","article-title":"Incidence of herpes zoster in patients with giant cell arteritis: a population-based cohort study","volume":"49","author":"Sch\u00e4fer","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2013.02.031_bib0095","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1365-2133.2007.07950.x","article-title":"Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion","volume":"157","author":"Fardet","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.revmed.2013.02.031_bib0100","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/acr.20062","article-title":"Malignancy risk in patients with giant cell arteritis: a population-based cohort study","volume":"62","author":"Kermani","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.revmed.2013.02.031_bib0105","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/rheumatology\/kep409","article-title":"Risk of cancer in patients with biopsy-proven giant cell arteritis","volume":"49","author":"Hill","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2013.02.031_bib0110","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.semarthrit.2007.03.006","article-title":"Cancer in biopsy-proven giant cell arteritis. A population-based study","volume":"37","author":"Gonzalez-Gay","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2013.02.031_bib0115","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1136\/ard.2005.036459","article-title":"Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica\/giant cell arteritis","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2013.02.031_bib0120","first-page":"303","article-title":"Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study","volume":"15","author":"Nesher","year":"1997","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2013.02.031_bib0125","first-page":"1484","article-title":"A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164\u00a0patients","volume":"27","author":"Chevalet","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2013.02.031_bib0130","first-page":"258","article-title":"Iatrogenic morbidity accompanying suppression of temporal arteritis by adrenal corticosteroids","volume":"16","author":"Rubinow","year":"1984","journal-title":"Ann Ophtalmol"},{"key":"10.1016\/j.revmed.2013.02.031_bib0135","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3899\/jrheum.101254","article-title":"Mortality in patients with biopsy-proven giant cell arteritis: a south australian population-based study","volume":"38","author":"Ninan","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2013.02.031_bib0140","first-page":"737","article-title":"Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden","volume":"29","author":"Uddhammar","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2013.02.031_bib0145","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/bmj.299.6698.549","article-title":"Death rates and causes of death in 284\u00a0consecutive patients with giant cell arteritis confirmed by biopsy","volume":"299","author":"Nordborg","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.revmed.2013.02.031_bib0150","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1136\/bmj.282.6260.269","article-title":"Prognosis in giant-cell arteritis","volume":"282","author":"Graham","year":"1981","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.revmed.2013.02.031_bib0155","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/hrt.2003.020180","article-title":"Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study","volume":"90","author":"Souverein","year":"2004","journal-title":"Heart"},{"issue":"Suppl. 1","key":"10.1016\/j.revmed.2013.02.031_bib0160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000314349","article-title":"Coagulopathy in Cushing's syndrome","volume":"92","author":"Trementino","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.revmed.2013.02.031_bib0165","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1210\/jc.2009-0290","article-title":"Hypercoagulable state in Cushing's syndrome: a systematic review","volume":"94","author":"Van Zaane","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.revmed.2013.02.031_bib0170","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/art.22548","article-title":"Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica","volume":"57","author":"Maradit Kremers","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2013.02.031_bib0175","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1176\/appi.ajp.2011.11071009","article-title":"Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care","volume":"169","author":"Fardet","year":"2012","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.revmed.2013.02.031_bib0180","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1749-6632.2009.04981.x","article-title":"Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy","volume":"1179","author":"Brown","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.revmed.2013.02.031_bib0185","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1001\/archinte.160.19.2917","article-title":"Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use","volume":"160","author":"Naganathan","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.revmed.2013.02.031_bib0190","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1046\/j.1525-1497.2002.10649.x","article-title":"Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly","volume":"17","author":"Blackburn","year":"2002","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.revmed.2013.02.031_bib0195","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0961203311402246","article-title":"Glucocorticoid-induced diabetes mellitus in patients with systemic lupus erythematosus treated with high-dose glucocorticoid therapy","volume":"20","author":"Ha","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2013.02.031_bib0200","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4158\/EP08331.RAR","article-title":"Glucocorticoid-induced hyperglycemia","volume":"15","author":"Clore","year":"2009","journal-title":"Endocr Pract"},{"key":"10.1016\/j.revmed.2013.02.031_bib0205","doi-asserted-by":"crossref","first-page":"c54","DOI":"10.1159\/000097598","article-title":"Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases","volume":"105","author":"Uzu","year":"2007","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.revmed.2013.02.031_bib0210","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0140-6736(97)03392-8","article-title":"Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids","volume":"350","author":"Garbe","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2013.02.031_bib0215","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/jama.280.6.539","article-title":"Association of inhaled corticosteroid use with cataract extraction in elderly patients","volume":"280","author":"Garbe","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2013.02.031_bib0220","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.revmed.2011.01.003","article-title":"[Ophthalmologic adverse effects of systemic corticosteroids]","volume":"32","author":"Lebreton","year":"2011","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2013.02.031_bib0225","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/00002512-199915060-00004","article-title":"Corticosteroids and glaucoma risk","volume":"15","author":"Tripathi","year":"1999","journal-title":"Drugs Aging"},{"key":"10.1016\/j.revmed.2013.02.031_bib0230","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1365-2133.2010.09877.x","article-title":"Impact of glucocorticoid-induced adverse events on adherence in patients receiving long-term systemic glucocorticoid therapy","volume":"163","author":"Arena","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.revmed.2013.02.031_bib0235","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1136\/ard.2007.072157","article-title":"EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases","volume":"66","author":"Hoes","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2013.02.031_bib0240","unstructured":"Osteoporose_synthese.pdf [Internet]. [cited 2012\u00a0June 12]. Available from: http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/osteoporose_synthese.pdf."},{"key":"10.1016\/j.revmed.2013.02.031_bib0245","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1210\/jcem-61-1-83","article-title":"Evidence that prednisone-induced myopathy is reversed by physical training","volume":"61","author":"Horber","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.revmed.2013.02.031_bib0250","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/00008483-199703000-00002","article-title":"Glucocorticoid-induced muscle atrophy. The role of exercise in treatment and prevention","volume":"17","author":"LaPier","year":"1997","journal-title":"J Cardiopulm Rehabil"},{"key":"10.1016\/j.revmed.2013.02.031_bib0255","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ophtha.2004.10.032","article-title":"Short-term tolerance of pulse methylprednisolone therapy in patients with diabetes mellitus","volume":"112","author":"Feldman-Billard","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2013.02.031_bib0260","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2265.2011.04242.x","volume":"77","author":"Yuen","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.revmed.2013.02.031_bib0265","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.revmed.2008.04.001","article-title":"[Long-term systemic corticosteroid-therapy associated measures: description of the French internal medicine physicians\u2019 practices]","volume":"29","author":"Fardet","year":"2008","journal-title":"Rev Med Interne"},{"issue":"8\u00a0Suppl.","key":"10.1016\/j.revmed.2013.02.031_bib0270","first-page":"19","article-title":"[Description of French general practitioners\u2019 practices regarding long term systemic corticosteroid therapy-associated measures]","volume":"59","author":"Perdoncini-Roux","year":"2009","journal-title":"Rev Prat"},{"key":"10.1016\/j.revmed.2013.02.031_bib0275","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.revmed.2009.03.009","article-title":"[Short-term effect of dietary-sodium intake on arterial blood pressure of patients treated with systemic corticosteroids: a prospective, randomised, crossover study]","volume":"30","author":"Fardet","year":"2009","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2013.02.031_bib0280","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4065\/82.9.1052","article-title":"Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials","volume":"82","author":"Green","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.revmed.2013.02.031_bib0285","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jinf.2006.01.016","article-title":"Severe strongyloidiasis in corticosteroid-treated patients: case series and literature review","volume":"54","author":"Fardet","year":"2007","journal-title":"J Infect"},{"key":"10.1016\/j.revmed.2013.02.031_bib0290","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.21705","article-title":"Glucocorticoid use, other associated factors, and the risk of tuberculosis","volume":"55","author":"Jick","year":"2006","journal-title":"Arthritis Rheum"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866313000775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866313000775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:32:25Z","timestamp":1759336345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866313000775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0248866313000775"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2013.02.031","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complications de la corticoth\u00e9rapie chez les patients souffrant de maladie de Horton ou de pseudopolyarthrite rhizom\u00e9lique","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2013.02.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Soci\u00e9t\u00e9 nationale fran\u00e7aise de m\u00e9decine interne (SNFMI). Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}